Catalyst Event
Medpace Holdings Inc (MEDP) · Other
From KEDI Global Longevity Bio Index (KGLB)
5/28/2026, 12:00:00 AM
General Counsel Stephen P. Ewald scheduled to sell 16,349 shares at $450.00 per share on May 28, 2026; this insider selling is estimated to cause a 1-5% price decline expected.
Korean Translation
2026년 5월 28일 법무 자문위원 스티븐 P. 월드의 보통주 16,349주(주당 450.00달러) 매도 예정임. 내부자 매도로 인한 심리 위축으로 1-5%의 주가 하락이 예상됨.
Related Recent Events
Exelixis Inc (EXEL) · Other
U.S. FDA PDUFA target action date for zanzalintinib (December 3, 2026) is a potential first approval for a major new franchise; >10% price impact is estimated, scheduled.
12/3/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Other
The U.S. FDA set a PDUFA target action date for iberdomide on 2026-08-17; importance is Low as the setting of a PDUFA date is a procedural event with minor price impact.
8/17/2026, 12:00:00 AM
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for its seasonal flu vaccine (mRNA-1010) on August 5, 2026; Medium importance as PDUFA dates are major catalysts for biotech stocks, scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Next quarterly earnings for Q2 2026 are expected to be announced on August 4, 2026; medium impact estimated based on historical volatility during earnings releases, expected.
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi's Q2 2026 earnings results release on July 30, 2026, is expected to have a Medium impact as earnings typically drive 5-10% price volatility scheduled.
7/30/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.
7/30/2026, 12:00:00 AM